IDH2 and hematologic disorder: A phase I, Multicenter, Open-Label, Dose-escalation and expansion, Safety, Pharmacokinetic, Pharmacodynamic, and clinical activity study of orally administered AG-881 in patients with advanced hematologic malignancies with an IDH1 and/or IDH2 mutation